Analysis of Simvastatin Usage in Hypertension Patients in Kediri City Health Center

Hypertension is a chronic condition characterized by increased blood pressure on the walls of the arteries. The use of simvastatin in hypertensive patients has proven to be useful in primary and secondary prevention of cardiovascular disease. The increase in blood sugar levels in long-term simvastatin users is caused by increased gluconeogenesis with increased gene expression of an enzyme that plays a role in increasing glucose production in the liver, namely phosphoenolpyruvate carboxykinase (PEPCK). The objective to analyze additional simvastatin therapy on a random plasma glucosa (GDA) Lipid levels in outpatient hypertensive patients at the Kediri City health center. This research method is analytical observational. The sampling technique for this research was using accidental sampling and time limited sampling. The patients obtained were 30, 3.3% women, 84% aged 46-59 years, 5, 10 mg amlodipine monotherapy, captropril 25 mg and 2 patients received polytherapy, namely amlodipine 10 mg + HCT 25 mg + lisinopril 10 mg ; captopril 25 mg + HCT 25 mg Based on the average levels of GDA pre 198.47 ± 10.3 mg/dl, GDA post 211.63 ± 12.62 mg/dl, LDL pre 88.43 ± 4,535 mg/dl and LDL post 79.60 ± 4,197 mg/dl. Shapiro Wilk Normality Test results of sig >0.05 indicate that the data is normal except trigliserida test. Conclusion: Based on the sig value of 0.00 in the inter-subject aspect test using SPPS 24 paired test and wilcoxon, it can be concluded that the use of simvastatin has a statistically significant effect on GDA, lipid levels in research subject.